tradingkey.logo
搜索

Alkermes Plc

ALKS
添加自选
55.080USD
0.0000.00%
收盘 06/26, 16:00美东报价延迟15分钟
9.09B总市值
59.24市盈率 TTM

Alkermes Plc

55.080
0.0000.00%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

0.00%

5天

+22.43%

1月

+47.47%

6月

+93.33%

今年开始到现在

+96.85%

1年

+91.05%

关键数据
--今开
0.000最高
0.00成交量
59.24市盈率 TTM
125.08市盈率动
--股息TTM
4.58%换手率
55.080昨收
0.000最低
0.00成交额
24.77市盈率静
5.25市净率
0.00%股息率 TTM
4.82%ROA
40.79052周最高
1.85量比
367.07M净利润
165.10M总股本
0.9298每股收益TTM
0.31Beta
9.36%ROE
25.16552周最低
5.47%振幅
81.36%毛利率
9.09B总市值
14.40回报/风险
2.24%风险率

TradingKey Alkermes Plc股票评分

单位: USD 更新时间: 2026-06-26

操作建议

Alkermes Plc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名3/387位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价48.12。中期看,股价处于上升通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Alkermes Plc评分

相关信息

行业排名
3 / 387
全市场排名
36 / 4566
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
极度看好

Alkermes Plc亮点

亮点风险
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
估值高估
公司最新PE估值59.24,处于3年历史高位
机构减仓
最新机构持股182.39M股,环比减少6.17%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值0.00

分析师目标

根据 17 位分析师
买入
评级
48.125
目标均价
-8.91%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Alkermes Plc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Alkermes Plc简介

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
公司代码ALKS
公司Alkermes Plc
CEOPops (Richard F)
网址https://www.alkermes.com/

常见问题

Alkermes Plc(ALKS)的当前股价是多少?

Alkermes Plc(ALKS)的当前股价是 55.08。

Alkermes Plc的股票代码是什么?

Alkermes Plc的股票代码是ALKS。

Alkermes Plc股票的52周最高点是多少?

Alkermes Plc股票的52周最高点是40.79。

Alkermes Plc股票的52周最低点是多少?

Alkermes Plc股票的52周最低点是25.16。

Alkermes Plc的市值是多少?

Alkermes Plc的市值是9.18B。

现在Alkermes Plc(ALKS)的股票是买入、持有还是卖出?

根据分析师评级,Alkermes Plc(ALKS)的总体评级为买入,目标价格为48.12。

Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是多少

Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是1.47。
KeyAI